Literature DB >> 11566160

Concurrent validation of schizotaxia: a pilot study.

W S Stone1, S V Faraone, L J Seidman, A I Green, J D Wojcik, M T Tsuang.   

Abstract

BACKGROUND: Many first-degree relatives of patients with schizophrenia show deficits in clinical, neuropsychological, neurobiological and social domains, in the absence of psychosis. We recently reformulated Meehl's concept of schizotaxia to conceptualize the liability to schizophrenia, and we proposed preliminary criteria based on the presence of negative symptoms and neuropsychological deficits. Here we investigate the concurrent validity of schizotaxia by comparing a group of subjects who met criteria for schizotaxia with a group who did not on independent measures of clinical function, and on lifetime rates of selected comorbid psychiatric disorders.
METHODS: Twenty-seven adults who were first-degree, biological relatives of patients with schizophrenia were evaluated for schizotaxia based on our predetermined criteria involving negative symptoms and neuropsychological deficits. Subjects also received portions of the Diagnostic Interview for Genetic Studies, the Structured Interview for Schizotypy, the Family Interview for Genetic Studies, the DSM-IV Global Assessment of Functioning, the Physical Anhedonia Scale, the Social Adjustment Scale and the Symptom Checklist-90-Revised. Subjects who met criteria for schizotaxia were compared with those who did not on each of the clinical measures, and on their rates of comorbid DSM-IV psychiatric diagnoses.
RESULTS: Eight subjects met criteria for schizotaxia, and 19 did not. Subjects with schizotaxia showed significantly lower levels of function on each of the clinical scales. Differences in comorbid psychiatric diagnoses were not significant, although the rate of lifetime substance abuse diagnoses in the schizotaxic group (50%) approached levels that are often seen in schizophrenia.
CONCLUSIONS: These findings provide the first evidence of concurrent validation for a proposed syndrome of schizotaxia. They are also consistent with the view that the vulnerability to schizophrenia may be defined, at least partially, although larger studies to assess both the concurrent and predictive validity of schizotaxia will be required to confirm these results.

Entities:  

Mesh:

Year:  2001        PMID: 11566160     DOI: 10.1016/s0006-3223(01)01116-7

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  6 in total

Review 1.  Schizotaxia: current status and future directions.

Authors:  Ming T Tsuang; William S Stone; Franziska Gamma; Stephen V Faraone
Journal:  Curr Psychiatry Rep       Date:  2003-06       Impact factor: 5.285

2.  Neurocognitive and clinical dysfunction in adult Chinese, nonpsychotic relatives of patients with schizophrenia: Findings from the Changsha study and evidence for schizotaxia.

Authors:  William S Stone; Xiaolu Hsi; Liwen Tan; Shaochun Zhu; Lingjiang Li; Anthony J Giuliano; Larry J Seidman; Ming T Tsuang
Journal:  Asian J Psychiatr       Date:  2012-03

3.  Predicting quality of life impairment in chronic schizophrenia from cognitive variables.

Authors:  Michael S Ritsner
Journal:  Qual Life Res       Date:  2007-04-03       Impact factor: 4.147

4.  Are neurocognitive, clinical and social dysfunctions in schizotaxia reversible pharmacologically?: Results from the Changsha study.

Authors:  William S Stone; Xiaolu Hsi; Anthony J Giuliano; Liwen Tan; Shaochun Zhu; Lingjiang Li; Larry J Seidman; Ming T Tsuang
Journal:  Asian J Psychiatr       Date:  2012-03

Review 5.  The link between schizophrenia and substance use disorder: A unifying hypothesis.

Authors:  Jibran Y Khokhar; Lucas L Dwiel; Angela M Henricks; Wilder T Doucette; Alan I Green
Journal:  Schizophr Res       Date:  2017-04-14       Impact factor: 4.939

6.  The silent side of the spectrum: schizotypy and the schizotaxic self.

Authors:  Andrea Raballo; Josef Parnas
Journal:  Schizophr Bull       Date:  2010-02-22       Impact factor: 9.306

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.